Drug Type Small molecule drug |
Synonyms Fimasartan/rosuvastatin, Rosuvastatin/fimasartan, Tuvero + [1] |
Target |
Action antagonists, inhibitors |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date South Korea (31 Aug 2016), |
Regulation- |
Molecular FormulaC22H28CaFN3O6S |
InChIKeyAVDMILNVMOXCHF-DHMAKVBVSA-N |
CAS Registry147098-20-2 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Dyslipidemias | South Korea | 31 Aug 2016 | |
| Hypertension | South Korea | 31 Aug 2016 |





